Exclusive Summary

• This FDA GMP certified Cladribine Injection, already registered in the US and holding over 55% market share, demonstrates strong competitiveness and acceptance in a mature market.
• Cladribine possesses clear clinical value for Hairy Cell Leukemia (HCL) treatment, is recommended by the WHO Essential Medicines List, and has growing potential in MS treatment, indicating robust and expanding market demand.
• The company's FDA registration and extensive international market experience, evidenced by its significant US market share, offer overseas pharmaceutical companies a low-risk, high-efficiency generic drug collaboration option.
• The cost advantage of this generic drug over the originator product will be a key selling point for global healthcare institutions and patients, especially amid the increasing global focus on healthcare cost containment.
• The product's stability under 2~8℃ storage meets international standards, facilitating global supply chain management and distribution.